Proton therapy for Hodgkin lymphoma

Bradford Hoppe, Roelf Slopsema, Lena Specht

    1 Citation (Scopus)

    Abstract

    Due to the high cure rates in Hodgkin lymphoma (HL) patients treated with combined-modality treatment, the subsequent late toxicities from treatment become increasingly important. Survivors of HL are at high risk for developing and dying from secondary cancers and heart diseases as a consequence of their treatment. Limiting the radiation to normal tissues using techniques that allow smaller radiation fields and lowering the total dose has already shown some improvement in reducing the subsequent late effects from radiotherapy. Proton therapy may also help decrease the amount of normal tissue irradiated, thereby reducing the subsequent late effects from radiotherapy.

    Original languageEnglish
    Title of host publicationRadiotherapy for Hodgkin lymphoma
    EditorsLena Specht, Joachim Yahalom
    Number of pages7
    Place of PublicationBerlin
    PublisherSpringer
    Publication date2011
    Pages197-203
    Chapter15
    ISBN (Print)978-3-540-78455-5
    ISBN (Electronic)978-3-540-78944-4
    DOIs
    Publication statusPublished - 2011

    Fingerprint

    Dive into the research topics of 'Proton therapy for Hodgkin lymphoma'. Together they form a unique fingerprint.

    Cite this